Protagenic Therapeutics Stock Performance
| PTIX Stock | USD 0.44 0.01 2.22% |
The company holds a Beta of 0.12, which implies not very significant fluctuations relative to the market. As returns on the market increase, Protagenic Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protagenic Therapeutics is expected to be smaller as well. At this point, Protagenic Therapeutics has a negative expected return of -0.38%. Please make sure to check Protagenic Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Protagenic Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:4 | Dividend Date 2016-07-27 | Last Split Date 2023-03-23 |
1 | Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of 1.275 Million | 10/29/2024 |
2 | Protagenic Therapeutics Inc. Warrant Quarterly 10-Q Report - Quartzy | 11/14/2024 |
3 | Protagenic Therapeutics faces Nasdaq delisting over equity deficit | 12/03/2024 |
4 | Acquisition by Arrow Alexander K. of 1000 shares of Protagenic Therapeutics at 2.29 subject to Rule 16b-3 | 12/20/2024 |
| Begin Period Cash Flow | 215.2 K | |
| Free Cash Flow | -3.9 M |
Protagenic |
Protagenic Therapeutics Relative Risk vs. Return Landscape
If you would invest 70.00 in Protagenic Therapeutics on October 20, 2024 and sell it today you would lose (26.00) from holding Protagenic Therapeutics or give up 37.14% of portfolio value over 90 days. Protagenic Therapeutics is currently does not generate positive expected returns and assumes 8.6386% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than Protagenic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagenic Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagenic Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protagenic Therapeutics, and traders can use it to determine the average amount a Protagenic Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0442
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PTIX |
Estimated Market Risk
| 8.64 actual daily | 76 76% of assets are less volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Protagenic Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protagenic Therapeutics by adding Protagenic Therapeutics to a well-diversified portfolio.
Protagenic Therapeutics Fundamentals Growth
Protagenic Stock prices reflect investors' perceptions of the future prospects and financial health of Protagenic Therapeutics, and Protagenic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagenic Stock performance.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | (1.67 M) | ||||
| Shares Outstanding | 6.79 M | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 4.42 X | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 655.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Earnings Per Share | (1.27) X | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
About Protagenic Therapeutics Performance
Evaluating Protagenic Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protagenic Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protagenic Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 269.53 | 275.10 | |
| Return On Tangible Assets | (1.33) | (1.40) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (1.23) | (1.17) |
Things to note about Protagenic Therapeutics performance evaluation
Checking the ongoing alerts about Protagenic Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagenic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagenic Therapeutics generated a negative expected return over the last 90 days | |
| Protagenic Therapeutics has high historical volatility and very poor performance | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protagenic Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Protagenic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagenic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagenic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagenic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagenic Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagenic Therapeutics' stock. These opinions can provide insight into Protagenic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.